A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancer
Interventions: DRUG: tucatinib|DRUG: trastuzumab deruxtecan
Sponsor: Seagen Inc.